Editorials

What Can We Learn from Treatment-Induced Changes in Rheumatoid Factor and Anti-Citrullinated Peptide Antibodies? F. Bobbio-Pallavicini, R. Caporali, S. Bugatti, C. Montecucco ............................................ 1903
Do Improved Survival Rates of Patients with Systemic Lupus Erythematosus Reflect a Global Trend? M. Abu-Shakra .................................................. 1906
Antiphospholipid Syndrome Nephropathy in Different Scenarios R.A. Asherson, E.M. Klumb .................................................. 1909

Articles

Genetic and Expression Analysis of CASP7 Gene in a European Caucasian Population with RA V.H. Teixeira, L. Jacq, S. Lasbleiz, et al, and The European Consortium on Rheumatoid Arthritis Families .......................... 1912
Granzyme B Induces Apoptosis of Chondrocytes with NK Cell-like Cytotoxicity in RA S. Saito, K. Murakoshi, S. Kotake, N. Kamatani, T. Tomatsu ............................... 1932
Safety of Anti-TNF-α Therapy in Patients with RA and Chronic HCV Infection C. Ferri, G. Ferraccioli, D. Ferrari, et al, for the GISEA Group ........................................ 1944
Arrhythmic Risk During Acute Infusion of Infliximab: A Prospective, Single-blind, Placebo-controlled, Crossover Study in Patients with Chronic Arthritis P.E. Lazzerini, M. Acampa, M. Hammoud, et al ........................................ 1958
Differential Response of the RF and Anticitrullinated Protein Antibodies During Adalimumab Treatment in Patients with RA W.H. Bos, G.M. Bartelds, G.J. Wolbink, et al .............................. 1972
APS Nephropathy in Catastrophic, Primary, and SLE-related APS M.G. Tektonidou, F. Sotsiou, H.M. Moutsopoulos ................................ 1983

Erythrocyte C4d and Complement Receptor 1 in SLE V. Singh, J.A. Mahoney, M. Petri ........................................ 1989
Efficacy of Rituximab in Limited WG with Refractory Granulomatous Manifestations P. See, U. Specks, K.A. Keogh ........................................ 2017
Beneficial Effects of Adalimumab on Biomarkers Reflecting Structural Damage in Patients with AS W.P. Maksymowych, P. Rahm, K. Shojania, et al, for the M03-606 Study Group ........................................ 2030
A Randomized Controlled Trial of Extracorporeal Shock Wave Therapy for Lateral Epicondylitis (Tennis Elbow) M.P. Staples, A. Forbes, R. Ptasznik, J. Gordon, R. Buchbinder ................................. 2038

Pediatric Rheumatology

HLA-B27 Predicts a More Extended Disease with Increasing Age at Onset in Boys with JIA L. Berntson, M. Damgård, B. Andersson-Gäre, et al, for the Nordic Paediatric Rheumatology Study Group ........................................ 2055

Images in Rheumatology

Catastrophic Rheumatoid Arthritis P.V. Voulgari, A.A. Drosos ........................................ 2062

Contents continued on page ii
Pulmonary Infarctions Due to Bilateral Pulmonary Arterial Thrombosis in a Lupus Patient with APS
C-T. Weng, L. Cheng, C-R. Wang .................................. 2064

Obituary Asherson’s Syndrome of the Catastrophic Antiphospholipid Antibodies
Y. Shoenfeld, R. Cervera ........................................ 2066

Correspondence
Sensitivity and Specificity of the CASPAR Criteria for PsA in a Family Medicine Clinic Setting
Reply W.J. Taylor ................................................. 2070
Subclinical Atherosclerosis in Patients with PsA
M.A. Gonzalez-Gay, T.R. Vazquez-Rodriguez,
C. Gonzalez-Juanatey, J. Llorca ................................ 2070

Letters
IFN-γ Is Associated with Vascular Endothelial Dysfunction in Patients with RA
L.M. Amezcua-Guerra, R. Márquez-Velasco,
R. Hernández-Ávalos, A. Vargas, R. Bojalil .................. 2071

Neuromuscular Involvement in Rheumatic Patients Treated with Anti-TNF Therapy — Three Examples
U. Kiltz, C. Fendler, J. Braun .................................. 2074

An Unusual “Gouty” Case of Back Pain and Fever
C.M. Riddell, M. Elliott, A.P. Cairns ............................ 2076

Differential Response of Psoriatic Onycho-Pachydermo-Periostitis to 2 Anti-TNF-α Agents
M.A. Kapusta, C. Dumont ....................................... 2077

Alemtuzumab (Campath-1H) for Treatment of Refractory Polymyositis
B. Thompson, P. Corris, J.A.L. Miller, R.G. Cooper,
J.P. Halsey, J.D. Isaacs ........................................ 2080

Early Callus Formation in Human Hip Fracture Treated with Internal Fixation and Teriparatide
C-T. Yu, J-K. Wu, C-C. Chang, C-L. Chen, J.C-C. Wei ...... 2082

Evaluation of a Knee and Shoulder Arthrocentesis Training Program for Primary Care Providers
H.R. Schumacher, L.X. Chen, L. Glick ......................... 2083

Correction
Canadian Consensus Practice Guidelines for Bisphosphonate Associated Osteonecrosis of the Jaw
A.A. Khan, G.K.B. Sándor, E. Dore, et al ..................... 2084

Meetings in Rheumatology ...................................... x